Skip to main content
Download PDF

Dexmedetomidine administration as a possible cognitive enhancer through increasing the level of brain-derived neurotrophic factors in surgical patients: a systematic review and meta-analysis

BMC Anesthesiology volume 24, Article number: 256 (2024) Cite this article

Abstract

Objective

This meta-analysis aimed to investigate the effect of dexmedetomidine on brain-derived neurotrophic factor (BDNF) levels in individuals undergoing various medical procedures. We systematically searched electronic databases and manually identified relevant articles to assess the impact of dexmedetomidine on BDNF levels in surgical patients.

Methods

A comprehensive literature search was conducted in PubMed, Scopus, Embase, and Web of Science databases with no language restrictions. Studies that examined the effects of dexmedetomidine administration on BDNF levels in surgical patients were included.

Results

The overall analysis revealed a statistically significant increase in BDNF levels in individuals receiving dexmedetomidine compared to controls (Standardized Mean Difference SMD = 1.65, 95% CI: 1.02 to 2.28; I2: 89%). Subgroup analyses based on the anesthesia method (p < 0.01), and the type of surgery (p < 0.01) showed significant between-group differences (Fig. 3). The results of the sensitivity analyses indicated that individual studies did not significantly affect the overall results.

Conclusion

This meta-analysis indicates that dexmedetomidine administration is associated with a significant increase in BDNF levels in individuals undergoing surgical procedures. These findings highlight the potential role of dexmedetomidine in modulating BDNF levels, which may have implications for optimizing perioperative neuroprotective strategies and improving patient outcomes.

Peer Review reports

Introduction

Dexmedetomidine is a highly selective α2-adrenergic agonist that has gained increasing attention in the field of anesthesia and perioperative medicine [1]. It is commonly used for its sedative and analgesic properties, offering an alternative to traditional sedatives and opioids [2]. In recent years, researchers have sought to explore the protective effects of dexmedetomidine, particularly on neurotrophic factors such as brain-derived neurotrophic factor (BDNF) in surgical patients [3].

BDNF is a neurotrophin that plays a crucial role in neuronal survival, growth, and synaptic plasticity [4]. It has been implicated in various neurological and psychiatric disorders [5], and its modulation may have implications for cognitive function and recovery in surgical patients [6]. In a previous meta-analysis, it has been reported that a decrease in BDNF levels is correlated with impaired cognition [7]. Also, Dexmedetomidine has been proposed as a modulator for BDNF levels post-operation, exerting a neuroprotective and anti-neuroinflammatory function [8].

Several studies have investigated the influence of dexmedetomidine on BDNF levels in post-surgical patients. Ge et al. [9] found that dexmedetomidine administration was associated with a significant increase in BDNF levels in patients undergoing carotid endarterectomy. In contrast to their findings is a study by Cheng et al. [10], who investigated the impact of dexmedetomidine on BDNF levels in patients undergoing total knee arthroplasty and found no significant change in BDNF levels compared to the control group.

These conflicting findings in the literature highlight the need for a systematic review and meta-analysis to provide a comprehensive evaluation of the effect of dexmedetomidine on BDNF levels in post-surgical patients. By synthesizing the available evidence, we aimed to determine the overall impact of dexmedetomidine on BDNF levels post-operation and explore potential factors that may explain the variability in the results, ultimately contributing to the advancement of perioperative care.

Method

The present systematic review was conducted based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and AMSTAR (Assessing the methodological quality of systematic reviews) guidelines and guidelines retrieved from the Cochrane Handbook for Systematic Reviews of Interventions [11].

Search strategy

We searched databases including PubMed, Web of Science, Scopus, and Embase up to 24 May 2023, using the search string with the combination of the following keywords: (“dexmedetomidine”) AND (“brain-derived neurotrophic factor” OR “BDNF”) AND (“surgery” OR “surgical patients”) (Supplementary File). No limitation was implemented on our search results. A second search was conducted one week before the submission in order to identify any newly published studies.

Eligibility criteria

Two reviewers, acting independently, initially evaluated the titles and abstracts of the identified articles to determine if they met the criteria for inclusion in the study, which focused on investigating the impact of dexmedetomidine administration on BDNF levels in patients who underwent any surgical procedure. Then, the full text of the initially identified studies was reviewed to make a final decision. All types of study designs, including RCTs, non-randomized controlled trials, observational studies, interrupted time series, and controlled before-and-after studies, were considered for inclusion in this study. The exclusion criteria consisted of irrelevant topics, articles that did not meet the mentioned inclusion criteria, review articles, meta-analyses, case reports, or animal studies. Disagreements between the reviewers were resolved through discussions and mutual agreement. There were no restrictions on the publication date or language of the included studies.

Screening and data extraction

The study selection process involved two independent reviewers and was conducted in two stages. During the first stage, the reviewers assessed the relevance of all identified articles by examining their titles and abstracts in relation to the research question and inclusion criteria. In the second stage, potentially eligible studies’ full texts were obtained and thoroughly reviewed for final inclusion. Data extraction was independently carried out by the same two reviewers, utilizing a pre-defined data extraction form.

Quality assessment

The quality of the included studies was independently assessed by the same two reviewers using appropriate tools based on the study design. For randomized controlled trials, the Cochrane Collaboration’s Risk of Bias tool was used. For observational studies, the Newcastle-Ottawa Scale was employed. Disagreements between reviewers were resolved through discussion or consultation with a third reviewer if necessary.

Data synthesis

A meta-analysis was conducted to determine the overall impact of dexmedetomidine administration on BDNF blood levels. To account for variations in BDNF measurement methods across studies, the standardized mean difference (SMD) was employed as the effect size metric. A random effect model was utilized to address potential heterogeneity among the included studies. Heterogeneity was assessed using the I^2 statistic, where values of 25%, 50%, and 75% indicated low, moderate, and high heterogeneity, respectively. Subgroup analyses were performed based on the source of BDNF, timing of assessment, and the anesthesia method. Sensitivity analysis was conducted using the leave-one out method to evaluate the robustness of the findings. To evaluate publication bias, both visual assessments using funnel plot asymmetry and statistical analysis using Egger’s regression test were employed. A symmetric funnel plot would suggest the absence of publication bias, while Egger’s test with a p-value less than 0.05 would indicate significant publication bias.

Results

Study selection

A total of 537 articles were found using electronic database searches, and 8 additional articles were identified manually. After removing duplicates, 321 articles underwent screening based on title and abstract. Among these, 24 articles were selected for a full-text assessment, and finally, 8 articles met the inclusion criteria and were included in the study [3, 8, 9, 12,13,14,15,16] (see Fig. 1 for the PRISMA flow diagram).

Fig. 1
figure 1

PRISMA flow diagram

Full size image

Study characteristics and quality assessment

Table 1 presents the characteristics of the included studies. The selected studies were published between 2013 and 2023. All studies were conducted in China. Among the included studies, 6 were randomized controlled trials (RCTs) [3, 8, 9, 12, 13, 16], and 2 were observational studies [14, 15]. The results of our quality assessments showed one study with a high risk of bias [12] (Supplementary File).

Table 1 Characteristics of included studies
Full size table

Meta-analysis

The meta-analysis included 8 studies, providing sufficient data for pooled effect size calculation. The pooled effect size indicated a statistically significant increase in BDNF levels in individuals who received dexmedetomidine compared to controls (SMD = 1.65, 95% CI: 1.02 to 2.28; I2: 89%) (Fig. 2).

Fig. 2
figure 2

Results of meta-analysis for the level of Brain-Derived Neurotrophic Factor (BDNF) levels dexmedetomidine administration

Full size image

Subgroup and sensitivity analyses

Subgroup analyses based on the anesthesia method (p < 0.01), and the type of surgery (p < 0.01) showed significant between-group differences (Fig. 3). However, there was no significant between-group difference after subgrouping studies based on source of BDNF and timing of the assessment. Sensitivity analyses were performed by excluding one study at a time to evaluate the impact of individual studies on the overall effect size. The results of the sensitivity analyses indicated that individual studies did not have a significant effect on the overall results (Fig. 4).

Fig. 3
figure 3

Results of subgroup analysis, (a) time of assessment; (b) source of BDNF; (c) type of anesthesia; and (d) type of surgery

Full size image
Fig. 4
figure 4

Results of sensitivity analysis

Full size image

Discussion

This report is the first systematic review of the literature evaluating the impact of dexmedetomidine on postoperative BDNF levels. Our data indicated that the perioperative use of dexmedetomidine caused a significantly lower reduction in BDNF levels compared to control groups. Moreover, we performed subgroup analysis based on outcomes and characteristics that had sufficient reported data among the studies for conducting the analysis, including BDNF sources, timing of assessment, and anesthesia method. The subgroup analysis revealed that the elapsed time between surgery and BDNF level evaluation, the source of BDNF, and the type of anesthesia (general anesthesia or spinal anesthesia) were all significant factors influencing the level of BDNF reduction. Our results are in concordance with results from preclinical studies demonstrating the neuroprotective effects of dexmedetomidine by increasing the expression of BDNF [17, 18].

A common neurological complication of surgery, postoperative cognitive dysfunction (POCD) is manifested clinically as declined learning, memory, concentration, and execution ability, hence negatively influencing patients’ lives [19]. Although the mechanisms of its pathogenesis remain largely unknown, a reduction in BDNF levels has recently been implicated as a pathway for POCD [20, 21]. Numerous animal and human studies have found that central BDNF levels decline post-operation, and have linked this reduction with inhibited neurogenesis [22], resulting in unfavorable postoperative cognitive outcomes [23]. This downregulation has been attributed to the preoperative general anesthetic agents [24] as well as the inflammation caused by the surgery itself [25]. Our study has demonstrated that the postoperative decrease in BDNF can be at least partly remedied by the use of dexmedetomidine, potentially alleviating cognitive dysfunction. In fact, four of the studies included have demonstrated that the use of dexmedetomidine can enhance postoperative neurocognitive outcomes compared to control groups [9, 12, 14, 26], with one directly associating cognitive function with BDNF levels [26]. It is also worth mentioning that our findings were in accordance with a multitude of systematic reviews examining the effects of dexmedetomidine on postoperative cognitive outcomes, with all concluding that dexmedetomidine has a favorable impact on such outcomes [27,28,29].

In one of our sub-group analyses, we compared BDNF levels in the blood after surgery based on the time of evaluation. Although the number of studies for each time-point is too small to infer any meaningful interpretations, we did find that BDNF levels 30 min after surgery do not seem to differ significantly between the dexmedetomidine group and the control group, and BDNF begins to fall after at least 6 h following surgery in the control groups, a decline that’s inhibited by dexmedetomidine administration. Yet, this inhibition appears to last only three days post-operation as BDNF levels after this time-point do not differ significantly between the two groups. This 66-hour-long time period is of special importance as complications such as postoperative delirium commonly develop during this phase [30], and postoperative cognitive dysfunction may follow [31]. BDNF has previously been proposed as a biomarker for postoperative delirium and postoperative cognitive dysfunction [31].

In another of our sub-group analyses, we compared the studies that evaluated serum BDNF levels post-operation with those that evaluated plasma BDNF. Plasma BDNF is believed to be more representative of central BDNF levels [32] in comparison to serum BDNF, and in our analysis, we found both to be significantly higher in the dexmedetomidine-administered group in comparison to controls. Although more studies measuring BDNF in each are required, based on the data we had it appears that dexmedetomidine is more effective at increasing plasma BDNF in comparison to serum BDNF. This finding is in accordance with preclinical studies observing dexmedetomidine penetrating the blood-brain barrier, potentially increasing central BDNF levels, which in turn increase plasma BDNF levels [1].

Ozer et al. [24] have shown that general anesthetics decrease BDNF levels following surgery, a decline not evident after administering spinal anesthetics. Therefore, we divided the studies based on the anesthetics they used as a control, and we noticed that dexmedetomidine, although more effective in elevating BDNF levels in both groups, was more effective in studies using general anesthetics than spinal ones. Although more research is required comparing dexmedetomidine with each type of anesthetic, it appears to be a viable alternative to other adjuvant anesthetics in general anesthesia, especially in older patients who are at a heightened risk of cognitive impairments [33].

This review has several potential limitations. First, five of the included studies had a sample size of less than one hundred patients, which are described as small studies. Therefore, our study may be subject to small study effect bias. Additionally, the duration and dosage of dexmedetomidine administration differed across studies and the influence of these factors on our results cannot be ruled out. In addition, the included studies performed different types of surgeries and the possible correlation of BDNF and type of the surgery after administration of dexmedetomidine needs further evaluation. Moreover, all studies included were carried out in China, not only increasing risk of publication bias, but also decreasing our ability to generalize these results to other ethnicities. It is also notable that we used circulating BDNF as a proxy for drawing conclusions about central BDNF. While this assumption is not baseless [32], central BDNF is surely the superior measure when discussing neuroprotection. Also, we performed meta-analysis on studies with different study designs, including RCTs and observational studies, which have different patient randomization processes, which may have a significant impact on the heterogeneity of the included studies.

Conclusion

This review indicated that the use of dexmedetomidine significantly lowers the reduction of circulating BDNF that usually follows anesthesia and surgery. This finding was more pronounced in plasma, in patients receiving general anesthesia, and in the relatively short term. Our results support the notion that dexmedetomidine exerts neuroprotective effects in patients undergoing surgery, although further research is needed to bolster these findings by examining the effects of dexmedetomidine on central BDNF levels.

Data availability

All data has been presented in the manuscript.

References

  1. Weerink MAS, Struys MMRF, Hannivoort LN, Barends CRM, Absalom AR, Colin P. Clinical pharmacokinetics and pharmacodynamics of Dexmedetomidine. Clin Pharmacokinet. 2017;56(8):893–913.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Tobias JD. Dexmedetomidine: applications in pediatric critical care and pediatric anesthesiology. Pediatr Crit Care Med. 2007;8(2):115–31.

    Article  PubMed  Google Scholar 

  3. Xing C, Yan C. Effects of dexmedetomidine on the incidence of postoperative delirium and plasma S-100β protein levels following hip surgery in the elderly population. Int J Gerontol. 2021;15(3):207–11.

    Google Scholar 

  4. Bekinschtein P, Cammarota M, Katche C, Slipczuk L, Rossato JI, Goldin A et al. BDNF is essential to promote persistence of long-term memory storage. Proceedings of the National Academy of Sciences. 2008;105(7):2711-6.

  5. Lu B, Nagappan G, Lu Y. BDNF and synaptic plasticity, cognitive function, and dysfunction. Neurotrophic factors. 2014:223 – 50.

  6. Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications. Archives Med Sci. 2015;11(6):1164–78.

    Article  CAS  Google Scholar 

  7. Xie B, Zhou H, Liu W, Yu W, Liu Z, Jiang L, et al. Evaluation of the diagnostic value of peripheral BDNF levels for Alzheimer’s disease and mild cognitive impairment: results of a meta-analysis. Int J Neurosci. 2020;130(3):218–30.

    Article  PubMed  Google Scholar 

  8. Cheng W, Wang M, Liu P, Zhao S, Liu X, Wang X. Protective effects of Dexmedetomidine and Oxycodone in patients undergoing limb ischemia-reperfusion. Med Sci Monitor: Int Med J Experimental Clin Res. 2019;25:9073–84.

    Article  CAS  Google Scholar 

  9. Ge Y, Li Q, Nie Y, Gao J, Luo K, Fang X, Wang C. Dexmedetomidine improves cognition after carotid endarterectomy by inhibiting cerebral inflammation and enhancing brain-derived neurotrophic factor expression. J Int Med Res. 2019;47(6):2471–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Cheng W, Zhang J, Wu Z, Sun X, Ren W. Protective effect of dexmedetomidine on Tourniquet induced lung injury in patients undergoing total knee arthroplasty: a randomized trial. Eur J Inflamm. 2023;21:1721727X231179671.

    Article  CAS  Google Scholar 

  11. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Zhang J, Wang G, Zhang F, Zhao Q. Improvement of postoperative cognitive dysfunction and attention network function of patients with ischemic cerebrovascular disease via dexmedetomidine. Experimental Therapeutic Med. 2018;15(3):2968–72.

    CAS  Google Scholar 

  13. Yang L, Xu JM, Jiang X, Ruan W, Cui Y, He L. Effect of dexmedetomidine on plasma brain-derived neurotrophic factor: a double-blind, randomized and placebo-controlled study. Ups J Med Sci. 2013;118(4):235–9.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Wei X, Zhou C, Ou Y, Qu Q. Administration of surgical anesthetic dexmedetomidine improves cognitive and neurological function in infants with congenital heart disease. Int J Clin Exp Med. 2019;12(6):7527–35.

    CAS  Google Scholar 

  15. Ding Q, Zhang X, Chen P. Intraoperative dexmedetomidine in Peripheral or Emergency neurologic surgeries of patients with mild-to-moderate traumatic brain injuries: a retrospective cohort study. Dose-response: Publication Int Hormesis Soc. 2020;18(2):1559325820920119.

    Article  CAS  Google Scholar 

  16. Cheng W, Zhang J, Wu Z, Sun X, Ren W. Protective effect of dexmedetomidine on Tourniquet induced lung injury in patients undergoing total knee arthroplasty: a randomized trial. Eur J Inflamm. 2023;21.

  17. Dong Y, Hong W, Tang Z, Gao Y, Wu X, Liu H. Dexmedetomidine attenuates neurotoxicity in developing rats Induced by Sevoflurane through Upregulating BDNF-TrkB-CREB and downregulating ProBDNF-P75NRT-RhoA signaling pathway. Mediators Inflamm. 2020;2020:5458061.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Li ZC, Jia YP, Wang Y, Qi JL, Han XP. Effects of dexmedetomidine post–treatment on BDNF and VEGF expression following cerebral ischemia/reperfusion injury in rats. Mol Med Rep. 2018;17(4):6033–7.

    CAS  PubMed  Google Scholar 

  19. Pappa M, Theodosiadis N, Tsounis A, Sarafis P. Pathogenesis and treatment of post-operative cognitive dysfunction. Electron Physician. 2017;9(2):3768–75.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Xue Z, Shui M, Lin X, Sun Y, Liu J, Wei C, et al. Role of BDNF/ProBDNF imbalance in postoperative cognitive dysfunction by modulating synaptic plasticity in aged mice. Front Aging Neurosci. 2022;14:780972.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Qiu LL, Pan W, Luo D, Zhang GF, Zhou ZQ, Sun XY, et al. Dysregulation of BDNF/TrkB signaling mediated by NMDAR/Ca(2+)/calpain might contribute to postoperative cognitive dysfunction in aging mice. J Neuroinflammation. 2020;17(1):23.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Travica N, Aslam H, O’Neil A, Lane MM, Berk M, Gamage E, et al. Brain derived neurotrophic factor in perioperative neurocognitive disorders: current evidence and future directions. Neurobiol Learn Mem. 2022;193:107656.

    Article  CAS  PubMed  Google Scholar 

  23. Wyrobek J, LaFlam A, Max L, Tian J, Neufeld KJ, Kebaish KM, et al. Association of intraoperative changes in brain-derived neurotrophic factor and postoperative delirium in older adults. Br J Anaesth. 2017;119(2):324–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Ozer AB, Demirel I, Erhan OL, Firdolas F, Ustundag B. Effect of different anesthesia techniques on the serum brain-derived neurotrophic factor (BDNF) levels. Eur Rev Med Pharmacol Sci. 2015;19(20):3886–94.

    CAS  PubMed  Google Scholar 

  25. Porter GA, O’Connor JC. Brain-derived neurotrophic factor and inflammation in depression: pathogenic partners in crime? World J Psychiatry. 2022;12(1):77–97.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Cheng XQ, Mei B, Zuo YM, Wu H, Peng XH, Zhao Q, et al. A multicentre randomised controlled trial of the effect of intra-operative dexmedetomidine on cognitive decline after surgery. Anaesthesia. 2019;74(6):741–50.

    Article  CAS  PubMed  Google Scholar 

  27. Fondeur J, Escudero Mendez L, Srinivasan M, Hamouda RK, Ambedkar B, Arzoun H, et al. Dexmedetomidine in Prevention of Postoperative Delirium: a systematic review. Cureus. 2022;14(6):e25639.

    PubMed  PubMed Central  Google Scholar 

  28. Govêia CS, Miranda DB, Oliveira LVB, Praxedes FB, Moreira LG, Guimarães GMN. Dexmedetomidine reduces postoperative cognitive and behavioral dysfunction in adults submitted to general anesthesia for non-cardiac surgery: meta-analysis of randomized clinical trials. Braz J Anesthesiol. 2021;71(4):413–20.

    PubMed  PubMed Central  Google Scholar 

  29. Zeng T, Lv J, Cui Y, Li XF, Zhang Q. Effectiveness of dexmedetomidine on postoperative cognitive dysfunction in elderly patients with fracture: a systematic review. Med (Baltim). 2023;102(11):e31749.

    Article  Google Scholar 

  30. Deiner S, Silverstein JH. Postoperative delirium and cognitive dysfunction. Br J Anaesth. 2009;103(Suppl 1):i41–6.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Androsova G, Krause R, Winterer G, Schneider R. Biomarkers Postoperative Delirium Cogn Dysfunct. 2015;7.

  32. Gejl AK, Enevold C, Bugge A, Andersen MS, Nielsen CH, Andersen LB. Associations between serum and plasma brain-derived neurotrophic factor and influence of storage time and centrifugation strategy. Sci Rep. 2019;9(1):9655.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Rundshagen I. Postoperative cognitive dysfunction. Dtsch Arztebl Int. 2014;111(8):119–25.

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This study did not receive funding, grant, or sponsorship from any individuals or organizations.

Author information

Authors and Affiliations

  1. School of Medicine, RWTH Aachen University, Aachen, Germany

    Masoud Dehbozorgi

  2. School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

    Fatemeh Fereidooni

  3. Department of Surgery, Shahid Madani Hospital, Alborz University of Medical Sciences, Karaj, Iran

    Ramin Bozorgmehr, Javad Zebarjadi Bagherpour & Arman Shafiee

  4. Student Research Committee, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran

    Arman Shafiee, Mohammad Javad Amini, Niloofar Seighali & Kyana Jafarabady

  5. School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    Ida Mohammadi, Shahryar Rajai Firouzabadi & Diba Akbarzade

  6. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

    Razman Arabzadeh Bahri

Authors
  1. Masoud Dehbozorgi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fatemeh Fereidooni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ramin Bozorgmehr
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Javad Zebarjadi Bagherpour
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Arman Shafiee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ida Mohammadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mohammad Javad Amini
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Niloofar Seighali
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kyana Jafarabady
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shahryar Rajai Firouzabadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Diba Akbarzade
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Razman Arabzadeh Bahri
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

M.D, F.F, A.S., R.B, J.Z: Conceptualization, Project Administration, Data curation, Writing- Original Draft, Writing – Review & Editing, Visualization. I.M, N.S, M.A, K.J: Validation, Resources, Methodology, Software, Formal analysis, Writing – Original Draft. S.R, D.A: Writing- Original Draft. R.A.: Data curation, Writing- Original Draft.

Corresponding authors

Correspondence to Ramin Bozorgmehr or Arman Shafiee.

Ethics declarations

Ethical approval

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dehbozorgi, M., Fereidooni, F., Bozorgmehr, R. et al. Dexmedetomidine administration as a possible cognitive enhancer through increasing the level of brain-derived neurotrophic factors in surgical patients: a systematic review and meta-analysis. BMC Anesthesiol 24, 256 (2024). https://doi.org/10.1186/s12871-024-02646-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12871-024-02646-y

Keywords

BMC Anesthesiology

ISSN: 1471-2253

Contact us